Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma

Background: Regorafenib is a second-line therapy drug used for advanced hepatocellular carcinoma (HCC). Unfortunately, the survival benefit of the patients receiving this treatment is modest, which may be attributed to drug resistance. In the present study, sphingosine kinase 2 (SphK2) was targeted...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Oncol
Autori principali: Shi, Weiwei, Zhang, Shan, Ma, Ding, Yan, Dongliang, Zhang, Guang, Cao, Yin, Wang, Zhongxia, Wu, Junhua, Jiang, Chunping
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2020
Soggetti:
Oncology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327090/
https://ncbi.nlm.nih.gov/pubmed/32670862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00694
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi